This article is more than 5 years old. Information may no longer be current.

Alcon reports 5.9% increase in global sales for third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

HUENENBERG, Switzerland — Alcon's global sales grew by 5.9% in the third quarter, and operating profit increased by 17%, the company announced in a press release.

Third-quarter global sales totaled $1.614 billion. Excluding foreign exchange fluctuations, the global sales increase was 9%. Operating profit totaled $578 million, or $84 million more than in the third quarter 2008, the release said.

Gross earnings for the third quarter totaled $594 million; net earnings, after income taxes, totaled $515 million, or $1.71 per diluted share. Basic earnings per common share were $1.72.

The operating profit margin rose from 32.4% to 35.8% of sales, due to cost management initiatives that reduced selling, general and administrative expenses.

U.S. sales increased 7.6% because of rising demand for prescriptions and strong performance in the glaucoma and AcrySof IOL markets. Global sales of advanced technology IOLs increased 34.2% because of growing U.S. market share gains of the AcrySof IQ ReSTOR +3.0 D IOL and increased use of the AcrySof IQ toric IOL, the release said.

Global glaucoma sales rose 18.2%, mainly due to a 23.6% increase in global sales of the Travatan (travoprost) line of ophthalmic solutions. The launch of the Constellation vitreoretinal system spurred a 19.5% increase in vitreoretinal product sales.